Sumatriptan-naproxen sodium in migraine: A review.

Autor: Wilcha RJ; Headache Group, NIHR King's Clinical Research Facility and SLaM Biomedical Research Centre, The Wolfson Sensory, Pain and Regeneration Research Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK., Afridi SK; Neurology Department, Guy's and St Thomas' NHS Foundation Trust, London, UK., Barbanti P; Headache and Pain Unit, IRCCS San Raffaele Roma, Rome, Italy.; San Raffaele University, Rome, Italy., Diener HC; Department of Neuroepidemiology, Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), Medical Faculty of the University Duisburg-Essen, Essen, Germany., Jürgens TP; Neurologisches Zentrum, Neurologische Klinik, KMG Klinikum Güstrow, Güstrow, Germany.; Klinik und Poliklinik für Neurologie, Kopfschmerzzentrum Nord-Ost, Rostock, Germany., Lanteri-Minet M; Pain Départment, CHU Nice and FHU InovPain Université Côte Azur, Nice, France.; Inserm U1107, Neuro-Dol, Trigeminal Pain and Migraine, Université Clermont Auvergne, Clermont-Ferrand, France., Lucas C; Pain Clinic, Service de Neurochirurgie, Hôpital Salengro, CHU de Lille, Lille, France., Mawet J; Emergency Headache Centre, Department of Neurology (J.M.), Lariboisiere Hospital, Assistance Publique des Hopitaux de Paris, Paris, France., Moisset X; CHU de Clermont-Ferrand, Inserm, Neuro-Dol, service de neurologie, Université Clermont-Auvergne, Clermont-Ferrand, France., Russo A; Department of Advanced Medical and Surgical Sciences, Headache Centre, University of Campania 'Luigi Vanvitelli', Naples, Italy., Sacco S; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Sinclair AJ; Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.; Department of Neurology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Sumelahti ML; Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland., Tassorelli C; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.; Headache Science & Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy., Goadsby PJ; Headache Group, NIHR King's Clinical Research Facility and SLaM Biomedical Research Centre, The Wolfson Sensory, Pain and Regeneration Research Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.; Department of Neurology, University of California, Los Angeles, California, USA.
Jazyk: angličtina
Zdroj: European journal of neurology [Eur J Neurol] 2024 Sep; Vol. 31 Suppl 2, pp. e16434.
DOI: 10.1111/ene.16434
Abstrakt: Background: Varied responses to acute migraine medications have been observed, with over one-third (34.5%) of patients reporting insufficient headache relief. Sumatriptan-naproxen sodium, a single, fixed-dose combination tablet comprising sumatriptan 85 mg and naproxen sodium 500 mg, was developed with the rationale of targeting multiple putative mechanisms involved in the pathogenesis of migraine to optimise acute migraine care.
Methods: A narrative review of clinical trials investigating sumatriptan-naproxen sodium for both adults and adolescents was performed in March 2024.
Results: Across a total of 14 clinical trials in nine publications, sumatriptan-naproxen sodium offered greater efficacy for 2-h pain freedom (14/14) and sustained pain-free response up to 24 h (13/14) compared with monotherapy and/or placebo for both adult and adolescent study participants with an acceptable and well-tolerated adverse effect profile. Clinical trial data also demonstrates the effectiveness of sumatriptan-naproxen sodium in participants with allodynia, probable migraine, menstrual-related migraine and those with poor responses to acute, non-specific, migraine medication.
Conclusions: Multi-mechanistic therapeutic agents offer an opportunity to optimise acute medications by targeting multiple mediators involved in the pathogenesis of migraine. Sumatriptan-naproxen sodium resulted in greater initial and sustained pain freedom, compared with either sumatriptan, naproxen-sodium and/or placebo, for the treatment of single or multiple attacks of migraine across both adult and adolescent study populations.
(© 2024 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.)
Databáze: MEDLINE
Externí odkaz: